Three Cases of <i>EGFR</i>-mutated Lung Cancer That Transformed to Small Cell Lung Cancer

DOI Web Site 15 References
  • Morinaga Daisuke
    Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
  • Sakakibara Jun
    Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
  • Furuta Megumi
    Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
  • Shinagawa Naofumi
    Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
  • Goda Tomohiro
    Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
  • Wakabayashi Kento
    Department of Surgical Pathology, Hokkaido University Hospital
  • Takakuwa Emi
    Department of Surgical Pathology, Hokkaido University Hospital
  • Takashina Taichi
    Department of Internal Medicine, Iwamizawa Municipal General Hospital
  • Konno Satoshi
    Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

Bibliographic Information

Other Title
  • 小細胞肺癌転化を来した<i>EGFR</i>遺伝子変異陽性肺癌の3例

Search this article

Abstract

<p>Background. Non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitor (TKI) treatment well; however, it subsequently develops resistance to these drugs. Several mechanisms underlying the development of resistance to EGFR-TKI have been reported. Although transformation to small cell lung cancer (SCLC) accounts for 2-15% of such cases, little is known about treatments or clinical outcomes. Case 1. A 66-year-old woman with EGFR-mutated NSCLC was observed to have pleural effusion and dissemination during the administration of osimertinib. Transformation to SCLC was found in the pathological cell block examination of pleural effusion. Case 2. A 47-year-old man with EGFR-mutated NSCLC was found to have elevated tumor marker levels (NSE and ProGRP) and progressive pleural dissemination during S-1 treatment. Transformation to SCLC was detected in the pathological examination of pleural dissemination. Case 3. A 67-year-old man with EGFR-mutated NSCLC was found to have enlargement of his primary tumor. Transformation to SCLC was observed in the rebiopsy specimen of the primary tumor. All three patients received cisplatin and irinotecan, and their disease was controlled after transformation to SCLC. Conclusion. Cisplatin and irinotecan may be potential treatments for patients with EGFR-mutated NSCLC after transformation to SCLC. However, the accumulation of cases is required as there are few detailed reports on this treatment.</p>

Journal

  • Haigan

    Haigan 62 (2), 107-114, 2022-04-20

    The Japan Lung Cancer Society

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top